Lys232

Site Information
FLKLEKGkFGMVLLK SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 466702

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 )
Relevant cell line - cell type - tissue:	HCC78 (pulmonary) ( 2 ) , HepG2 (hepatic) ( 5 ) , SW48 (intestinal) ( 3 , 4 ) , SW480 (intestinal) ( 1 )

References
1	Li Y (2006) CST Curation Set: 1971; Year: 2006; Biosample/Treatment: cell line, SW480/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
2	Possemato A (2006) CST Curation Set: 1808; Year: 2006; Biosample/Treatment: cell line, HCC78/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
3	Li Y (2006) CST Curation Set: 1564; Year: 2006; Biosample/Treatment: cell line, SW48/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
4	Li Y (2006) CST Curation Set: 1565; Year: 2006; Biosample/Treatment: cell line, SW48/untreated &'\|\|' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
5	Mitchell J (2005) CST Curation Set: 1018; Year: 2005; Biosample/Treatment: cell line, HepG2/-; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info